This Orphan Drug Designation from the USFDA underlines the urgent medical need to develop a therapy for sickle cell disease
US revenue increased 43% to $12.9 billion, fueled by a 50% jump in volume, partially offset by a 7% decline in realized prices
Venglustat, a glucosylceramide synthase inhibitor (GCSi), works by reducing the abnormal buildup of sugar-and-fat molecules in cells and organs
The company’s total income jumped 31% year-on-year to Rs 125.5 crore
rofitability showed strong momentum, with EBITDA rising 44.9% YoY to Rs. 8,697 million
The base Gland business posted ?11,790 million in revenue, up 16% YoY
The platform uses cutting-edge AI and automation to tackle the entire revenue cycle
The development marks an important step in Sigachi's strategic focus on expanding its presence in complex, high-value specialty APIs, aligned with global demand for advanced therapies in rare and chronic disease segments
The Co-Dx PCR platform is designed to deliver gold-standard PCR accuracy in a compact, user-friendly device suitable for decentralized testing environments
The primary goal of the collaboration is joint research into trending and next-generation molecules
Subscribe To Our Newsletter & Stay Updated
